Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L. Riely GJ, et al. Among authors: morgensztern d. J Natl Compr Canc Netw. 2024 May;22(4):249-274. doi: 10.6004/jnccn.2204.0023. J Natl Compr Canc Netw. 2024. PMID: 38754467
Prognostic factors influencing survival in solitary plasmacytoma.
Ramsingh G, Mehan P, Morgensztern D, Luo J, Vij R. Ramsingh G, et al. Among authors: morgensztern d. Br J Haematol. 2009 May;145(4):540-2. doi: 10.1111/j.1365-2141.2009.07637.x. Epub 2008 Mar 2. Br J Haematol. 2009. PMID: 19298587 Free article. No abstract available.
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma.
Lossos IS, Hosein PJ, Morgensztern D, Coleman F, Escalón MP, Byrne GE Jr, Rosenblatt JD, Walker GR. Lossos IS, et al. Among authors: morgensztern d. Leuk Lymphoma. 2010 Mar;51(3):406-14. doi: 10.3109/10428190903518345. Leuk Lymphoma. 2010. PMID: 20038221 Clinical Trial.
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Bagegni NA, Park H, Kraft K, O-Toole M, Gao F, Waqar SN, Ratner L, Morgensztern D, Devarakonda S, Amin M, Baggstrom MQ, Liang C, Selvaggi G, Wang-Gillam A. Bagegni NA, et al. Among authors: morgensztern d. Cancer Chemother Pharmacol. 2022 Apr;89(4):487-497. doi: 10.1007/s00280-022-04406-6. Epub 2022 Mar 5. Cancer Chemother Pharmacol. 2022. PMID: 35247086 Free PMC article. Clinical Trial.
170 results